Search company, investor...

Base Pair Biotechnologies

Founded Year



Loan | Alive

Total Raised


Last Raised

$250K | 3 yrs ago

About Base Pair Biotechnologies

Base Pair Biotechnologies is a provider of highly customized aptamer discovery and development services. Base Pair offers a full suite of aptamer discovery and development and assay development services designed to generate Aptamers That Work for specific applications. In addition, the company offers a growing menu of catalog aptamers that have been developed to selectively bind specific targets.

Headquarters Location

8619 Broadway Street Suite 100

Pearland, Texas, 77584,

United States


Missing: Base Pair Biotechnologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Base Pair Biotechnologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Base Pair Biotechnologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Base Pair Biotechnologies is included in 1 Expert Collection, including Advanced Materials.


Advanced Materials

1,275 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

Base Pair Biotechnologies Patents

Base Pair Biotechnologies has filed 30 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Biotechnology, DNA, Nucleic acids, Genetics


Application Date


Grant Date



Related Topics

Molecular biology, Biotechnology, DNA, Nucleic acids, Genetics



Latest Base Pair Biotechnologies News

Aptamers Market Size to Reach USD 5,950 Million Driven By Growing Awareness towards the Benefits of Aptamers over Antibodies Exclusive Report by Acumen Research and Consulting

Jul 18, 2022

By Reading Time: 4 minutes Acumen Research and Consulting recently published report titled “Aptamers Market Size, Share, Analysis Report and Region Forecast, 2022 – 2030” LOS ANGELES, July 18, 2022 (GLOBE NEWSWIRE) — The Global Aptamers Market size accounted for USD 1,229 Million in 2021 and is expected to reach the value of USD 5,957 Million by 2030 at a CAGR of 19.6% during the forecast period from 2022 to 2030. Aptamers are molecules of peptides or oligonucleotides that bind to a specific protein, lipid, or nucleic acid molecules. Aptamers are easily synthesized and used for protein detection, inhibition, and characterization. Aptamers could be used in conjunction with small molecules, antibodies, and other aptamers as pharmaceutical leads, detection reagents, and functional proteomic levels. Aptamers can be genetically engineered to have higher affinity and specificity for a variety of targets. Aptamers can be selected from pools of random-sequence oligonucleotides and used to bind a wide range of biomedically relevant proteins with antibody-like binding affinity and specificities. Aptamers are adaptable and cost-effective, and they can be used in addition to or instead of antibodies. Aptamers have recently received a lot of attention for potential diagnostic and therapeutic purposes, and they have surpassed antibodies in popularity because of their key advantages: lower cost, ability to not destroy neighboring cells, higher binding affinity, longer shelf life, and high specificity. Aptamers’ distinctive characteristics have strongly affected the healthcare industry, allowing corporations to significantly increase their influence in order to capitalize on the enormous potential of aptamers, serving as a significant development opportunity that will propel market growth. Request For Free Sample Report @ Regional Scope Key Companies Profiled Aptagen, LLC, SomaLogic, Aptamer Sciences Inc., Noxxon Pharma, Vivonics Inc., TriLink Biotechnologies, Base Pair Biotechnologies Inc., Aptus Biotech S.L., Raptamer Discovery Group, AM Biotechnologies, and Neoventures Biotechnology Inc. Report Coverage Customization Scope Global Aptamers Market Growth Aspects The increasing number of clinical trials and research for the development of aptamer-based therapeutic applications, raised awareness about the benefits of aptamers over monoclonal antibodies, increasing investment in pharmaceutical research, and increasing occurrence of severe and genetic disorders all contribute to the growth of the aptamers market. Growth in venture capital funding for aptamer studies, as well as expanding partnerships with research organizations and the pharmaceutical industry, are expected to provide market participants with a broad range of opportunities for growth. On the other hand, a relatively low acknowledgment in comparison to monoclonal antibodies is likely to restrain market growth, while a shortage of qualified and trained professionals may pose a challenge to market expansion. The high efficiency and low cost of aptamers in binding to complex molecules when compared to antibodies, combined with an increased emphasis on optimizing the technology, are the key factors driving the market value of aptamers. Increasing extensive Research and development capabilities in the pharmaceutical and biotechnology industries have also aided the aptamers industry’s growth. The increased recombinant production process, combined with the increasing emphasis on aptamers for pharmaceutical research and medical interventions, has generated valuable aptamers market growth opportunities. Increasing FDA authorizations have also assisted market growth and accelerated market growth. Check the detailed table of contents of the report @ Growing Number of Applications is expected to propel the Market Aptamer products have the potential to be used as diagnostic research agents, biosensors, biomarkers, or drug development tools. Precision medicine and bio-industrial applications benefit from it as well. Moreover, it allows for the natural selection of new substances in whole animal experiments, reducing false starts and requiring healthy animals for drug testing. All of these factors have contributed to an increase in the number of businesses investing in this market. Furthermore, the rise in the prevalence of life-threatening conditions such as cancer has urged numerous companies to develop new detecting assays based on aptamers therapies, which will drive the aptamers market. Aptamers Market Regional Overview North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa are the regional classification of the global aptamers market. North America will lead the global aptamers market in 2021, with the highest revenue share. Rising chronic disease incidence, good healthcare infrastructure, and growing interest in the aptamer profession by research institutes are some of the important factors contributing to the region’s superiority. The United States is expected to have an impact on the North American aptamer market owing to the enhanced registration of innovative therapeutics by research organizations. Furthermore, the collaborative experience of the developed regions’ leading companies to force their way into emerging economies is propelling the Asia-Pacific aptamers market forward. During the forecast period, extensive R&D expenditures in the pharmaceutical and biotechnology industries greatly helped the growth of the aptamers market. Aptamers Market Segmentation The global aptamers market has been segmented by Acumen Research and Consulting based on type, application, and end-user. Based on the type, the market is divided into nucleic acid aptamers, and peptide aptamers. Based on the application, the market separatedinto diagnostics, research and development, therapeutics, and others. Based on end-user, the market is categorized into pharmaceutical & biotechnology companies, academic & government research institutes, CROs, and others. Buy this premium research report – Aptamers Market Players Some key players covered global in the aptamers industry are Aptagen, LLC, Soma Logic, Aptamer Sciences Inc., Noxxon Pharma, Vivonics Inc., TriLink Biotechnologies, Base Pair Biotechnologies Inc., Aptus Biotech S.L., Raptamer Discovery Group, AM Biotechnologies, and Neoventures Biotechnology Inc. Browse More Research Topic Healthcare Sector: The Global Hospital Acquired Infection Control Market is anticipated to grow at a CAGR of around 5.1% during the forecast period 2021 to 2028 and to reach around USD 7.8 Billion by 2028. The Global Medical Equipment Calibration Service Market is expected to grow at a CAGR of around 10.6% from 2021 to 2028 and expected to reach the market value of around USD 5.6 Billion by 2028. The Global Veterinary Artificial Insemination Market is expected to grow at a CAGR of around 5.5% from 2021 to 2028 and expected to reach the market value of around USD 6,780.5 Million by 2028. Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise. For Latest Update Follow Us on Twitter and, LinkedIn Contact Us:

Base Pair Biotechnologies Frequently Asked Questions (FAQ)

  • When was Base Pair Biotechnologies founded?

    Base Pair Biotechnologies was founded in 2012.

  • Where is Base Pair Biotechnologies's headquarters?

    Base Pair Biotechnologies's headquarters is located at 8619 Broadway Street, Pearland.

  • What is Base Pair Biotechnologies's latest funding round?

    Base Pair Biotechnologies's latest funding round is Loan.

  • How much did Base Pair Biotechnologies raise?

    Base Pair Biotechnologies raised a total of $5.31M.

  • Who are the investors of Base Pair Biotechnologies?

    Investors of Base Pair Biotechnologies include Paycheck Protection Program, National Institute on Drug Abuse, Centers for Disease Control and Prevention, BioTex Finance, Eventi Capital Partners and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.